Steatohepatitis
| Steatohepatitis | |
|---|---|
| Diagnosis in short | |
|
Steatohepatitis. Trichrome stain. | |
|
| |
| LM | steatosis (usually macrovesicular); hepatocyte injury -- ballooning degeneration (key feature), Mallory bodies; portal bridging (late stage) |
| Subtypes | by etiology (classically): ASH, NASH -- all almost histologically identical |
| LM DDx | steatosis, Wilson disease, hepatitis C, drug-induced liver disease |
| Gross | pale/yellowish, often enlarged |
| Site | liver - see medical liver disease |
|
| |
| Associated Dx | obesity, alcohol abuse |
| Prevalence | common |
| Prognosis | dependent on underlying cause |
| Treatment | dependent on underlying cause |
Steatohepatitis is a fatty change of the liver (steaosis) with (histologic) evidence of liver injury. It can be due to a number of different causes.
General
- Steatohepatitis is a label for a set of histopathologic findings.
- Fat accumulation (in hepatocytes) alone is liver steatosis.
- It may be a pattern seen in drug toxicity, e.g. methotrexate toxicity.[1]
Etiology:
- Alcohol = alcoholic steatohepatitis (ASH).
- Not alcohol = non-alcoholic steatohepatitis (NASH).
- Drug/toxin.[2]
Notes:
- Pathologists can comment on the etiology; however, the histomorphology is not distinctive. In other words, ASH and NASH are clinical diagnoses.
- Steatohepatitis is a misnomer. It is not an -itis; inflammation is not the (predominant) pathologic process.
Microscopic
Features:
- Steatosis (usually macrovesicular) - key feature.
- If less than 10% ... consider alt. diagnosis/disease process.
- Hepatocyte injury:
- Ballooning degeneration - key feature. †
- Mallory bodies.
- Mallory body wannabes: "occasional cytoplasmic clumping".
- +/-Chicken-wire perisinusoidal fibrosis +/- zone III (centrilobular) fibrosis (early).
- Late-stage disease - portal bridging.[3]
Note:
- † Brunt does not require ballooning to be present to call steatohepatitis;[4] however, a table in a later paper Brunt paper (surveying pathologists) suggest that a significant number of pathologist may consider it a required finding.[5]
DDx:
- Steatosis - lacks ballooning degeneration and neutrophils.
- Wilson disease.
- Hepatitis C.
- Drug-induced liver disease.
Image
-
Steatohepatitis. (WC)
Grading steatohepatitis
A simple grading system
| Grade | Characteristics |
|---|---|
| 1 | steatosis, occasional ballooning, scattered PMNs |
| 2 | steatosis, obvious ballooning, obvious PMNs, chronic inflammation |
| 3 | panacinar steatosis, obvious ballooning |
Brunt grading system
Brunt's 1999 paper proposed a system:[4]
| Grade | Steatosis | Neutrophils | Ballooning | Chronic inflammation |
|---|---|---|---|---|
| 1 | <=66% | scattered, rare | occasional or absent (zone 3) | none or mild acinar, none or mild portal |
| 2 | any amount (>33%) | present | obvious ballooning | mild or moderate acinar, mild or moderate portal |
| 3 | panacinar, zone 3 predominant | present | present, obvious | mild acinar inflammation, mild or moderate (not marked) portal |
Clinical Research Network system
Nonalcoholic steatohepatitis Clinical Research Network system for scoring activity - adapted from Brunt and Tiniakos:[6]
| Score | Steatotic hepatocytes (%) |
Foci of lobular lymphocytes |
Ballooning heptocytes |
|---|---|---|---|
| 0 | <5% | none | none |
| 1 | 5-33% | <2 | few |
| 2 | 34%-66% | 2-4 | many |
| 3 | >66% | >4 | (not assigned) |
Staging steatohepatitis
| Stage | Fibrosis | Notes |
|---|---|---|
| 0 | none | - |
| 1 | zone 3 perisinusoidal | may be focal or extensive |
| 2 | perisinusoidal and periportal | no bridging |
| 3 | bridging fibrosis | no nodule formation |
| 4 | nodule formation | - |
Images
Steatohepatitis Brunt necroinflammatory grade 3, Brunt fibrosis stage 1 (not shown). Panacinar steatosis with unremarkable, small triads (UL 40X). Ballooning degeneration, with cytoplasmic tufts (arrows) (UR 400X). Lipogranuloma (LL 400X). Triad with mild chronic inflammation without interface hepatitis (LR 400X).
See also
References
- ↑ Schumacher, JD.; Guo, GL. (Nov 2015). "Mechanistic review of drug-induced steatohepatitis.". Toxicol Appl Pharmacol 289 (1): 40-7. doi:10.1016/j.taap.2015.08.022. PMID 26344000.
- ↑ Farrell, GC. (2002). "Drugs and steatohepatitis.". Semin Liver Dis 22 (2): 185-94. doi:10.1055/s-2002-30106. PMID 12016549.
- ↑ Gramlich, T.; Kleiner, DE.; McCullough, AJ.; Matteoni, CA.; Boparai, N.; Younossi, ZM. (Feb 2004). "Pathologic features associated with fibrosis in nonalcoholic fatty liver disease.". Hum Pathol 35 (2): 196-9. PMID 14991537.
- ↑ 4.0 4.1 Brunt, EM.; Janney, CG.; Di Bisceglie, AM.; Neuschwander-Tetri, BA.; Bacon, BR. (Sep 1999). "Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions.". Am J Gastroenterol 94 (9): 2467-74. doi:10.1111/j.1572-0241.1999.01377.x. PMID 10484010.
- ↑ Brunt, EM. (2001). "Nonalcoholic steatohepatitis: definition and pathology.". Semin Liver Dis 21 (1): 3-16. PMID 11296695.
- ↑ Brunt, EM.; Tiniakos, DG. (Nov 2010). "Histopathology of nonalcoholic fatty liver disease.". World J Gastroenterol 16 (42): 5286-96. PMID 21072891.




